Sponsored content brought to you by
Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize properties, and propose new molecules at speeds that were unimaginable only a few years ago. But that acceleration is creating another challenge: The capacity to generate candidates is beginning to outstrip the industry’s ability to test them.
“AI can rapidly identify and design hundreds or thousands of promising molecules,” says Derek Chen, PhD, senior director, antibody drug discovery at ProBio. As a result, he says, “the challenge has shifted from generating candidates to identifying which candidates are truly worth advancing.”
The bottleneck moves downstream
Drug discovery has traditionally been constrained by the difficulty and cost of identifying promising starting points. AI is loosening that constraint, enabling researchers to explore more molecular possibilities and computationally prioritize designs.
Experimental biology, however, cannot necessarily accelerate at the same pace. Every AI-generated candidate must still confront biological reality. Researchers need to establish whether a molecule produces the desired functional response, behaves as expected in relevant biological systems, and possesses properties compatible with further development. As Chen says, each candidate must undergo “functional screening, developability assessment, safety evaluation, and preclinical testing.”
That shifts the bottleneck downstream. Instead of struggling to generate enough interesting molecules, discovery organizations can face more computationally attractive candidates than their laboratories can efficiently validate.
Chen says this shift is increasing the importance of experimental capabilities including “high-throughput affinity screening, functional and mechanism-of-action assays, developability assessment, immunogenicity testing, advanced in vitro models, and translational in vivo studies.”
A prediction is not a medicine
Computational promise and therapeutic potential are not the same. Predicted affinity or potency might move a candidate forward, but successful medicines must satisfy a much broader set of requirements.
“A promising computational prediction is only the starting point,” says Wenwan Fang, PhD, product manager, discovery at ProBio. A candidate must demonstrate the desired biological activity and mechanism of action while also possessing “favorable safety, pharmacokinetic, and developability characteristics.”
A molecule that performs impressively computationally or in an early assay might still prove unstable, difficult to manufacture at scale, or unsuitable because of immunogenicity or other development risks.
“Ultimately, the most valuable candidates are those that combine strong biological performance with the practical attributes required for successful development and commercialization,” Fang says.
For Chen, that makes prioritization increasingly important. “Success depends not on creating more molecules, but on validating and prioritizing the right ones quickly and efficiently,” he says.
Building validation at AI speed
Keeping pace with AI will likely require more than simply adding laboratory capacity. Companies might need to rethink how validation is integrated into discovery.
“As AI dramatically increases the number of potential drug candidates generated, organizations will need to invest in technologies that accelerate validation rather than discovery alone,” Fang says.
Those investments could include laboratory automation, robotic liquid handling, high-throughput screening platforms, advanced cell-based and functional assays, and integrated data-management systems. Fang also expects growing demand for technologies that assess developability, safety, and manufacturability earlier, alongside more predictive in vitro and in vivo models.
The objective is a tighter feedback loop: AI proposes candidates, experiments test them, and experimental data inform subsequent designs.
Finding molecules that matter
Although better AI models will remain important, Chen sees integration as the larger opportunity. “The greatest competitive advantage is likely to come from tighter integration between computational prediction and experimental validation,” he says. Organizations that create “seamless feedback loops between AI-driven design and high-quality experimental data” will be best positioned to accelerate discovery, reduce development risk, and improve the likelihood of clinical success.
For Fang, the most valuable investments are similarly those that help researchers “rapidly identify which AI-generated candidates are truly worth advancing into development.”
Explore More www.probiocdmo.com/add-aidd-solution.html
